Investor Asks To Replead Medtronic Securities Suit

Law360, New York (March 26, 2009, 12:00 AM EDT) -- The lead plaintiff in a securities class action against Medtronic Inc. alleging that the company covered up fatal defects in its Sprint Fidelis defibrillator leads has asked to replead the case, which was dismissed earlier this month, in light of new information from the U.S. Food and Drug Administration.

The plaintiff, investor Stanley Kurzweil, said in a motion filed Tuesday in the U.S. District Court for the District of Minnesota that only days after the case was dismissed, the FDA produced over 2,000 pages of its...
To view the full article, register now.